title: Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer.
abstract: BACKGROUND
  Management of metastatic castration refractory prostate cancer (CRPC) is rapidly evolving. Rationalisation of treatment requires identification of those patients more likely to benefit from a particular therapy. We reviewed the outcome of patients treated with abiraterone at our Institution to describe factors predictive for response.
  
  
  METHODS
  Patients with CRCP treated with abiraterone were identified. Baseline variables and potential prognostic factors were extracted from electronic records. Outcome measures included overall survival (OS), prostate-specific antigen (PSA) response and time to PSA progression (TTPP). The Kaplan-Meier method and Cox proportional hazards model were used to analyze survival data.
  
  
  RESULTS
  A total of 61 patients met the inclusion criteria. In multivariate analysis, three independent predictors of OS were identified: Duration of response to androgen deprivation therapy (ADT) (hazard ratio(HR)=0.95, p=0.006), performance status (HR=7.4, p=0.013), and baseline haemoglobin (HR=0.47, p≤0.001).
  
  
  CONCLUSIONS
  This study has identified three factors predictive for response to abiraterone in CRPC. Duration of response to ADT has not been previously shown to be a predictive factor for patients with CRCP. We suggest that a prospective validation is required.
authors: Queen Elizabeth Hospital Birmingham, Birmingham University Hospitals, Birmigham, U.K.
authors: Mehran
authors: M
authors: Afshar
authors: Queen Elizabeth Hospital Birmingham, Birmingham University Hospitals, Birmigham, U.K.
authors: Fawaz
authors: F
authors: Al-Alloosh
authors: School of Cancer Sciences, University of Birmingham, Birmingham, U.K.
authors: Sarah
authors: S
authors: Pirrie
authors: Queen Elizabeth Hospital Birmingham, Birmingham University Hospitals, Birmigham, U.K.
authors: Clare
authors: C
authors: Rowan
authors: Queen Elizabeth Hospital Birmingham, Birmingham University Hospitals, Birmigham, U.K. Cancer Research Centre, University of Warwick, Warwick, U.K.
authors: Nicholas D
authors: ND
authors: James
authors: Queen Elizabeth Hospital Birmingham, Birmingham University Hospitals, Birmigham, U.K. e.porfiri@bham.ac.uk.
authors: Emilio
authors: E
authors: Porfiri
mesh_terms: D000328:Adult; D000368:Aged; D000736:Androstenes / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000736:Androstenes; D000970:Antineoplastic Agents; C089740:abiraterone
keywords: Abiraterone; CRPC; metastatic prostate cancer; predictive algorithm